• Image 01
  • Image 02
  • Image 03
  • Image 04
  • Image 05
  • Image 06
Need assistance? Contact Us: 1-800-255-5897

Menu

  • Home
  • About Us
    • Company Overview
    • Management Team
    • Board of Directors
  • Your Loan Service Center
  • MAKE A PAYMENT
  • Business Service Center
  • Contact Us
  • Home
  • About Us
    • Company Overview
    • Management Team
    • Board of Directors
  • Your Loan Service Center
  • MAKE A PAYMENT
  • Business Service Center
  • Contact Us
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Kairos Pharma, Ltd. Common Stock (NY:KAPA)

0.3410 -0.0190 (-5.28%)
Official Closing Price Updated: 8:00 PM EDT, Aug 14, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 184,742
Open 0.3492
Bid (Size) 0.3430 (100)
Ask (Size) 0.3534 (3,000)
Prev. Close 0.3600
Today's Range 0.3331 - 0.3534
52wk Range 0.2695 - 2.110
Shares Outstanding 20,821,353
Dividend Yield N/A
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News
What's going on in today's after hours session ↗
July 22, 2026
Via Chartmill
These stocks have an unusual volume in today's session ↗
July 22, 2026
Via Chartmill

Performance

YTD
-53.2%
-53.2%
1 Month
+0.3%
+0.3%
3 Month
-29.0%
-29.0%
6 Month
-42.1%
-42.1%
1 Year
-71.6%
-71.6%

More News

Read More
TinyGemsBreaks – Kairos Pharma Ltd. (NYSE American: KAPA) Collaborates With Bayer to Evaluate Combination Therapy for Advanced Prostate Cancer
July 22, 2026
Via Investor Brand Network
News headline image
Kairos Pharma Announces Strategic Collaboration with Bayer to Enhance XOFIGO Activity in Metastatic Prostate Cancer
July 22, 2026
From Kairos Pharma, Ltd
Via Business Wire
The trading volume of these stocks is deviating from the norm in today's session. ↗
July 17, 2026
Via Chartmill
What's going on in today's pre-market session ↗
July 17, 2026
Via Chartmill
In today's session, these stocks are experiencing unusual volume. ↗
July 16, 2026
Via Chartmill
BioMedNewsBreaks — Kairos Pharma Ltd. (NYSE American: KAPA) Reports Favorable Interim Phase 1 Safety Data for ENV-105 in EGFR-Mutated Lung Cancer
July 15, 2026
Via Investor Brand Network
News headline image
Kairos Pharma Reports Breakthrough Interim Safety Data in Phase 1 Trial of ENV-105 in EGFR-Mutated Lung Cancer Patients — Targeting a $10 Billion Drug Resistance Market
July 15, 2026
From Kairos Pharma, Ltd
Via Business Wire
TinyGemsBreaks – Kairos Pharma Ltd. (NYSE American: KAPA) Highlights Pipeline Expansion and Clinical Milestones in Mid-Year Shareholder Update
June 04, 2026
Via Investor Brand Network
News headline image
Kairos Pharma Recaps Important Acquisitions and Details Plans for the Balance of 2026 in Letter to Shareholders
June 04, 2026
From Kairos Pharma, Ltd
Via Business Wire
BioMedNewsBreaks – Kairos Pharma Ltd. (NYSE American: KAPA) Receives 2026 Healthcare Innovation Award for Drug Resistance Research
May 14, 2026
Via Investor Brand Network
News headline image
Kairos Pharma Receives GHP Magazine’s Healthcare & Pharmaceutical Award
May 14, 2026
From Kairos Pharma, Ltd
Via Business Wire
InvestorNewsBreaks – Kairos Pharma Ltd. (NYSE American: KAPA) to Present at LD Micro Invitational XVI
May 13, 2026
Via Investor Brand Network
TinyGemsBreaks – Kairos Pharma Ltd. (NYSE American: KAPA) Sets Virtual Annual Meeting, Discloses Going Concern Notice
May 11, 2026
Via Investor Brand Network
Topics Regulatory Compliance
News headline image
Kairos Pharma, Ltd. Sets Annual Meeting of Shareholder Date and Provides Update on Its Annual Filings
May 08, 2026
From Kairos Pharma, Ltd
Via Business Wire
InvestorNewsBreaks – Kairos Pharma Ltd. (NYSE American: KAPA) Earns 2026 Pinnacle Award for Biotech Innovation in Cancer Drug Resistance
April 15, 2026
Via Investor Brand Network
News headline image
Kairos Pharma Recognized with Pinnacle Award for Excellence in Healthcare Innovation
April 15, 2026
From Kairos Pharma, Ltd
Via Business Wire
News headline image
Kairos Pharma Investor News: Rosen Law Firm Encourages Kairos Pharma, Ltd. Investors to Inquire About Securities Class Action Investigation – KAPA
April 12, 2026
From Rosen Law Firm, P.A.
Via Business Wire
News headline image
Rosen Law Firm Encourages Kairos Pharma, Ltd. Investors to Inquire About Securities Class Action Investigation – KAPA
April 11, 2026
From The Rosen Law Firm, P.A.
Via Business Wire
BioMedNewsBreaks — Kairos Pharma Ltd. (NYSE American: KAPA) Enters Binding Terms To Acquire CL-273 For EGFR-Mutant Lung Cancer
March 02, 2026
Via Investor Brand Network
News headline image
Kairos Pharma Announces Signing of Binding Strategic Asset Acquisition of Exclusive Worldwide Rights to CL-273 From OrbiMed and Torrey Pines Investment-Backed Celyn Therapeutics
March 02, 2026
From Kairos Pharma, Ltd
Via Business Wire
Wondering what's happening in today's after-hours session? ↗
February 26, 2026
Via Chartmill
BioMedNewsBreaks – Kairos Pharma Ltd. (NYSE American: KAPA) Signs Term Sheet to Acquire Two Clinical-Stage NSCLC Assets
February 26, 2026
Via Investor Brand Network
Get insights into the top gainers and losers of Thursday's pre-market session. ↗
February 26, 2026
Via Chartmill

Frequently Asked Questions

Is Kairos Pharma, Ltd. Common Stock publicly traded?
Yes, Kairos Pharma, Ltd. Common Stock is publicly traded.
What exchange does Kairos Pharma, Ltd. Common Stock trade on?
Kairos Pharma, Ltd. Common Stock trades on the New York Stock Exchange
What is the ticker symbol for Kairos Pharma, Ltd. Common Stock?
The ticker symbol for Kairos Pharma, Ltd. Common Stock is KAPA on the New York Stock Exchange
What is the current price of Kairos Pharma, Ltd. Common Stock?
The current price of Kairos Pharma, Ltd. Common Stock is 0.3410
When was Kairos Pharma, Ltd. Common Stock last traded?
The last trade of Kairos Pharma, Ltd. Common Stock was at 08/14/26 08:00 PM ET
What is the market capitalization of Kairos Pharma, Ltd. Common Stock?
The market capitalization of Kairos Pharma, Ltd. Common Stock is 7.10M
How many shares of Kairos Pharma, Ltd. Common Stock are outstanding?
Kairos Pharma, Ltd. Common Stock has 7M shares outstanding.
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.

Having difficulty making your payments? We're here to help! Call 1-800-255-5897

Copyright © 2019 Franklin Credit Management Corporation
All Rights Reserved
Contact Us | Privacy Policy | Terms of Use | Sitemap